BRIEF-Immunocellular receives regulatory nod to start ICT-107 phase 3 trial

* Receives regulatory approval in Canada, the UK and the Netherlands to initiate ICT-107 Phase 3 trial in newly diagnosed glioblastoma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.